The KidDO project aims to identify metabolites that can predict the phenotype of kidney cells during Chronic Kidney Disease (CKD) and find out how these can drive in the progession of CKD. The KidDO team hopes to identify metabolites that can be used as diagnostic biomarkers and future therapeutic targets. Researchers from AstraZeneca are industry partners in KidDO.
On this page, you can find all of the news from ODIN, which is related to the KidDO project. If you are curious about more information, you are always welcome to contact Robert Fenton, who is head of the KidDO project.
KidDO is short for "Open discovery of metabolic targets for therapeutic intervention in kidney disease"
In ODIN, all findings and results will be shared openly.
Researchers working on ODIN projects are encouraged to upload all of their findings to the ODIN community on Zenodo - see the link to the right.
If you have any questions, you are more than welcome to contact the ODIN secretariat.